Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LINKER-AL2 study of linvoseltamab in relapsed or refractory systemic light chain amyloidosis
jRCT2031260635Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of linvoseltamab in light-chain amyloidosis (2 arms), sponsored by Regeneron Pharmaceuticals. Started Nov 2026; status: recruiting.
02
Drugs
linvoseltamab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on jRCT2031260635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260635.